Abstract:Backgroundbeta-thalassemia is one of the most common genetic diseases in the world and requires extensive therapy. Lentiviral-mediated gene therapy has been successfully exploited in the treatment of beta-thalassemia and showed promise in clinical application. Using a human beta-globin transgenic mouse line in a beta-thalassemia diseased model generated with a lentiviral-mediated approach, we investigate the stable therapeutic effect on a common thalassemia syndrome.Design and MethodsHuman beta-globin gene lentiviral vector was constructed, followed by subzonal microinjection into single-cell embryos of beta(IVS-2-654)-thalassemia mice to generate a transgenic line. Human beta-globin gene expression was examined with RT-PCR, Western-blotting and ELISA. The hematologic parameters and tissue pathology were investigated over time in founder mice and their off-spring.ResultsTransgenic mice with stable expression of the lentivirus carrying human beta-globin gene were obtained. A marked improvement in red blood cell indices and a dramatic reduction in red blood cell anisocytosis, poikilocytosis and target cells were observed. Nucleated cell proportion was greatly decreased in bone marrow, and splenomegaly with extramedullary hematopoiesis was ameliorated. Iron deposition in liver was also reduced. There was a two-fold increase in the survival rate of the beta(IVS-2-654)( )mice carrying human beta-globin transgene. Significantly, the germline integration of the lentiviral construct was obtained and stable hematologic phenotype correction was observed over the next two generations of the transgenic mice.ConclusionsThe generation of human beta-globin transgenic mice in a beta(IVS-2-654)-thalassemia mouse mediated with lentiviral vectors provides a useful model and offers an attractive means to investigate the transgenic stable therapeutic effect in beta-thalassemia.

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Therapeutic Effects of Induced Pluripotent Stem Cells in Chimeric Mice with Β-Thalassemia.

A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model

Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Cloning of Human Thalassemic Mutation Β41/42 and Establishment of Its Mammalian Expression System

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Site-specific Transfer of an Intact Β-Globin Gene Cluster Through a New Targeting Vector

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Therapeutic Effects of Induced Pluripotent Stem Cells in Chimeric Mice with Β-Thalassemia.

A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model

Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Cloning of Human Thalassemic Mutation Β41/42 and Establishment of Its Mammalian Expression System

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

Correction of RNA splicing defect in β&lt;sup&gt;654&lt;/sup&gt;-thalassemia mice using CRISPR/Cas9 gene-editing technology

Site-specific Transfer of an Intact Β-Globin Gene Cluster Through a New Targeting Vector

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology